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EFFECTIVE RNA LOADING OF CD34 DERIVED DENDRITIC CELLS FOR
ADOPTIVE IMMUNOTHERAPY
Hsu, A.K.W., Kerr, B.M., Allan, C.P., Turtle, C.J., Hart, D.N.J.,
Rice, A.M. Mater Medical Research Institute, South Brisbane, Queens-
land, Australia.
A successful immunotherapeutic strategy for the treatment of
relapsed Acute Lymphoblastic Leukemia (ALL) post stem cell
transplantation requires the optimisation of multiple parame-
ters. The aim of this project was to optimise RNA loading
conditions into dendritic cells (DC) for eventual induction of
leukemia speciﬁc cytotoxic T lymphocyte (CTL) responses. We
hypothesized that electroporation would be an efﬁcient tech-
nique with which to introduce IVT-RNA into cord blood
CD34derived DC. The aims of this project were to: 1) to
optimise variables affecting transfection efﬁciency (using IVT-
enhanced green ﬂuorescent protein (eGFP) mRNA as a model
antigen), 2) optimise variables affecting cell viability, 3) deter-
mine the optimal day of RNA loading and 4) show that the
electroporated CD34 derived DC were functional. We de-
signed experiments to investigate the effects of cuvette size, cell
concentration, voltage, capacitance and electroporation medium
on the viability and transfection efﬁciency of CD34derived
DC. Additionally, we investigated factors pre and post electro-
poration including: incubation times and exposure of cells to
different temperature environments that can inﬂuence viability
and GFP uptake by CD34derived DC. Using our optimal
conditions we achieved 91% GFP transfection efﬁciency with
90% cell viability, and 94% of Lin-CD11cHLA-DR DC have
taken up RNA. A crucial ﬁnding was the effect of temperature
on cell membranes, signiﬁcantly affecting transfection efﬁ-
ciency and cell survival. Cells will take up more RNA and
survive better in a warm (37oC) environment compared to room
temperature or ice. Transfection efﬁciency of CD34derived
DC electroporated on day 9 of culture was consistently higher
that that observed on day 7 of culture. Interestingly, electropo-
ration did not further upregulate activation markers on
CD34derived DC. CD34derived DC electroporated with Flu
Matrix protein RNA under the optimised conditions are able to
present antigen and be killed by ﬂu CTL clones. In conclusion,
we have developed an efﬁcient and safe electroporation proce-
dure that results in functional RNA loaded CD34derived DC
that can now be used to stimulate CTL for adoptive immuno-
therapy.
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RAPAMYCIN-GENERATED CD4, TH2 CELLS MODULATE GRAFT-VER-
SUS-HOST REACTION VIA AN IL-4 DEPENDENT MECHANISM
Foley, J., Jung, U., Henrikson, R., Fowler, D. National Cancer Insti-
tute, NIH, Bethesda, MD.
Augmentation of T cell replete allografts with donor Th2 cells
represents an approach to achieve a balance of type I and type II
cytokine immunity post-BMT for mediation of a graft-versus-
tumor (GVT) effect with regulation of graft-versus-host disease
(GVHD). We have recently found that in vitro usage of high-
dose rapamycin (10 uM) generates murine Th2 cells that po-
tently inhibit allograft CD4 and CD8 T cell acquisition of
IFN-based allospeciﬁcity, promote type II cytokine production
in vivo, and reduce GVHD while preserving a component of
GVT effect against allogeneic breast cancer cells. Because ra-
pamycin-generated Th2 cells secreted reduced IL-4 and greatly
reduced IL-5, IL-10, and IL-13 relative to control Th2 cells, we
hypothesized that this population might regulate graft-versus-
host reaction (GVHR) through a non-IL-4 mechanism. To
address this possibility, CD4 T cells from wild-type (wt) or
IL-4 knock-out (IL-4 KO) donor C57Bl/6 mice were co-stim-
ulated with anti-CD3, anti-CD28 coated beads in media sup-
portive of Th2 differentiation (IL-4, IL-2, IL-7) either
without (“Th2”) or with rapamycin (10 uM; “Th2.rapa”). Th2
or Th2.rapa cells generated from IL-4 KO donors were indeed
deﬁcient in IL-4 secretion, but otherwise secreted a similar
Th2-type cytokine pattern as Th2 or Th2.rapa cells expanded
from wt donors. As shown (Table), relative to wt Th2 cells, wt
Th2.rapa cells expanded greater in vivo after semi-allogeneic
BMT (B6-into-CB6F1; 1050 cGy XRT; BMT supplemented
with 20 x 106 donor GVHR-inducing T cells) and more potently
inhibited allograft CD4 and CD8 T cell acquisition of IFN-
allospeciﬁcity; Th2.rapa cells also yielded a more dramatic shift
toward type II cytokine secretion post-BMT (increased IL-4,
IL-5, IL-10, and IL-13; each p  0.05). In marked contrast,
IL-4 deﬁcient Th2 or Th2.rapa cells failed to modulate GVHR,
as such recipients had levels CD4 and CD8 IFN-allospeci-
ﬁcity similar to the GVHR control group. In conclusion, rela-
tive to control Th2 cells, rapamycin generated donor Th2 cells
have an increased capacity to inhibit GVHR; although Th2.rapa
cells secrete reduced IL-4 and greatly reduced IL-5, IL-10, and
IL-13 in vitro, their ability to induce these cytokines in vivo
post-BMT is signiﬁcantly increased. Both Th2 and Th2.rapa
cells are fully dependent upon IL-4 secretion for their inhibition
of GVHR, and as such, these cells operate through a conven-
tional Th2-type mechanism.
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RISK FACTORS OF DEVELOPING ACUTE GRAFT-VERSUS-HOST DISEASE
(AGVHD) AFTER HLA-MATCHED UNRELATED DONOR (MUD) TRANS-
PLANTATION -IMPORTANCE OF MAINTAINING THE BLOOD LEVEL OF
TACROLIMUS EARLY AFTER TRANSPLANTATION
Okamoto, S., Iguchi, T., Mori, T., Watanabe, R., Aisa, Y., Shimizu, T.,
Yokoyama, A., Ikeda, Y. Division of Hematology, Keio University School
of Medicine, Tokyo, Japan.
The aim of this study was to identify risk factors for moderate to
severe AGVHD in adults after MUD marrow transplantation and
prophylaxis with tacrolimus and methotrexate (MTX). Seventy ﬁve
adults with leukemia or marrow failure received a myeloablative
preparative regimen and unmanipulated bone marrow graft from a
HLA-serologically matched (50 allele match, 25 allele mismatch)
unrelated donor. Tacrolimus (0.03 mg/kg/day) was given by con-
tinuous infusion from day -1 and the dose was adjusted to maintain
whole blood steady state or trough levels between 10 and 20 ng/ml.
MTX was administered on days 1,3,6, /-11. 36 (48%) patients
Table. Th2.rapa Cells Potently Inhibit GVHR Via an
IL-4–dependent Mechanism
Total # Donor T Cellsb
# IFN- Allospecific
Cellsc
Trx Groupa CD4 CD8 CD4 CD8
1 (no Th2) 5.2  0.5 17.4  1.9 1.5  0.3 2.5  0.6
2 (Th2 wt) 15.0  2.1* 11.4  1.2* 0.9  0.2* 0.2  0.1*
3 (Th2 IL-4
KO) 15.1  1.5* 24.0  1.6† 1.5  0.2† 5.1  0.9†
4 (Th2.rapa) 35.6  2.5* 6.4  0.2* 0.4  0.1* 0.1  0.1*
5 (Th2.rapa
IL-4 KO) 25.6  1.2* 10.1  1.3† 1.9  0.5† 2.1  0.5†
aCB6F1 mice were lethally irradiated (1050 cGy; n  5 per trx group). Each mouse
received B6 marrow (1  106) and B6 T cells (20  106). Groups 2-5 received in
vitro–generated donor Th2 cells (10  106 cells) that were generated from wild-type or
IL-4 KO donors, and were generated either without or with rapamycin (10 M).
bAbsolute # of donor CD4 and CD8 splenic T cells was enumerated at day 7 post BMT
using ﬂow cytometry. cDay 7 splenic T cells were stimulated in vitro with CB6F1
dendritic cells, and the # of CD4 and CD8 cells producing IFN-	 was determined by
cytokine capture ﬂow cytometry. *Value is statistically different (P  0.05) relative to the
GVHR control group (group 1). †Value for the IL-4 KO group is statistically different
from the result obtained with the respective wild type Th2 or Th2.rapa cohort (that is,
group 5 vs. group 4 and group 3 vs. group 2).
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